| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.0016 | 1 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.0067 | 1 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0014 | 1 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.00097 | 1 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.0044 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00095 | 1 |